Table 4 Effect of presence of aGVHD (grades II–IV) compared to those without aGVHD at same time point, based on propensity-weighteda models for quality of life patient-reported outcomes after adjusting for baseline values and cohort.

From: The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill

Assessment

Estimate (95% CI)

P value

Depression

3.13 (−1.77, 8.04)

0.19

Anxiety

0.94 (−1.20, 3.08)

0.35

Fatigue, intensity

0.37 (−0.63, 1.36)

0.43

Fatigue, duration

2.56 (0.36, 4.76)

0.03

Fatigue, interference

1.01 (−0.08, 2.10)

0.07

Pain, intensity

0.25 (−0.66, 1.17)

0.55

Pain, interference

0.12 (−0.95, 1.19)

0.81

Sleep

−0.06 (−1.98, 1.87)

0.95

  1. aPropensity scores were obtained using a logistic regression model with age, sex, BMI, CMV status, conditioning regimen, and donor type as predictors of study group.
Back to article page